Phase II Study of XXXX and @entity2879 as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer.

@entity632 @entity1 @entity137 @entity417 @entity786 @entity2879 @entity1945 @entity1891 @entity204 @entity151 @entity3028 @entity3895
PURPOSE: @entity151 ( @entity151 ) has a poor prognosis, and current salvage chemotherapy for refractory @entity151 , such as @entity3895 ( @entity786 , @entity632 , @entity1891 ) or @entity1945 , has an unsatisfactory outcome, with a response rate and overall survival of less than 10% and 6 months, respectively. This phase II study evaluated the role of @entity1945 combined with @entity2879 in @entity151 @entity1 that have progressed, or relapsed, within 3 months following completion of the initial chemotherapy. MATERIALS AND METHODS: Twenty-seven @entity1 were entered into this study. Eligible @entity1 had an ECOG performance status of less than, or equal to, 2, at least one bidimensionally measurable lesion and adequate end organ function. IV @entity1945 , 1.0 mg/m2/d for 5 consecutive days, and @entity2879 , 100 mg/m2/d through days 1 to 3, were administered every 3 weeks until disease progression or undue @entity137 . RESULTS: The major @entity137 was myelosuppression. Grade 3/4 @entity417 , @entity3028 , and thrombocy-topenia occurred in 14.2, 34.8, and 27.3% of cycles, respectively. There was no treatment-related @entity204 , and other non-hematologic @entity137 were generally mild. Four @entity1 achieved partial responses, with a response rate RR of 14.8%. The progression-free survival PFS ranged from 1 to 7 months, with a median of 2.0 months (95% confidence interval 1.22~2.78 months). Twenty-five @entity1 died, with a median overall survival of 5.5 months (ranging from 1 to 21 months, 95% CI 4.32~6.68 months), and the 6-month survival rate was 32.1% (95% confidence interval 14.4~49.8%). CONCLUSION: The combination of @entity1945 and @entity2879 chemotherapy showed a modest response rate, but failed to prolong survival of refractory @entity151 @entity1 compared to @entity1945 monotherapy.
